

### UCLA Health

# **Reduced Readmissions with Enoxaparin Bridging for Subtherapeutic INR in MCS**

T Khuu, EC DePasquale, A Salimbangon, A Chang, E Moreno, D Rourke, J Creaser, E Vandenbogaart, AD Rahman, D Lai, R Ardehali, A Baas, M Cadeiras, D Cruz, MC Deng, MH Kwon, A Nsair, A Ardehali

# Background

Readmissions following mechanical circulatory support (MCS) device implantation continue to be frequent, and supra/subtherapeutic INR remain a major indication for readmission.

## Methods

- An outpatient enoxaparin protocol was developed and a pilot treatment period was initiated between August 2016 to October 2017
- Enoxaparin/INR managed by UCLA CMY APNs, PharmD and MCS MD.
- Inclusion Criteria:
  - 1. HeartMate II or HVAD device
  - 2. >30 days post-implant
  - 3. No active bleeding
  - 4. No history of major bleeding
  - 5. No history of thrombosis

- Several studies have shown the relative safety and efficacy of enoxaparin bridging in MCS, while some report an increased risk of bleeding.
- Consequently, there is no consensus on optimal management of subtherapeutic INR in MCS recipients.

# **Objectives**

We sought to assess whether outpatient enoxaparin in MCS recipients significantly reduced hospital readmissions while maintaining safe and effective anticoagulation.

- Patients who remain subtherapeutic >5 ulletdays on warfarin and enoxaparin are to be admitted for heparin bridging
- All-cause readmission rates were  $\bullet$ compared between the treatment period and the year prior.
- **Exclusion Criteria**:

6. INR < 1.7

- 1. Device other than HMII/HVAD
- 2. <30 days post-implant
- 3. Active bleeding
- 4. History of major bleeding
- 5. History of thrombotic event

Patient Characteristics			
	Historical Group No Enoxaparin N (%)	Study Period: Enoxaparin Bridge N (%)	% Change
Total MCS Readmissions	66	44	
Readmission Reason			
HF Symptoms	15	16	
Low INR	15	5	
Infection	9	6	
Anemia	5	0	
Bleeding	5	2	
Thrombosis	2	4	
Other	15	11	
INR Readmissions	15(22.7)	5 (11.4)	-49.8%
INR Median LOS	3	3	
HMII INR Readmissions	9 (13.6)	1 (2.3)	-83.1%
HVAD INR Readmissions	4 (6.1)	4 (9.1)*	




Figure 1. Device distribution among all readmits (n) between October 2015 to July 2017

Figure 2. Patient Characteristics. \*Three admissions for one HVAD BiVAD patient not eligible for enoxaparin protocol during study period.

## Results

- During the study period, ten patients were bridged with 20 courses of enoxaparin for INR < 1.7.  $\bullet$
- MCS readmissions for INR were reduced by 49.8% compared to historical period.  $\bullet$
- HMII INR readmission reduced 83.1%
- Earliest treatment day: POD 43  $\bullet$
- Median INR at enoxaparin start: 1.6 Median INR at enoxaparin stop: 2.3  $\bullet$
- The median dose received was 0.56 mg/kg/dose. A median of 6 doses (approx. 3 days) was required. All patients returned to the rapeutic INR with enoxaparin the rapy in under 5 days.
- There were **no bleeding or thrombotic events** in treated patients at any time.  $\bullet$

### Conclusions

Outpatient enoxaparin bridging for subtherapeutic INR in MCS recipients can be safe, effective, and greatly reduce readmission rates

Acknowledgements No Disclosures